The Evolving Landscape of Lung Cancer Treatment

Explore the latest advancements in lung cancer treatment in this informative webinar presented by Professor Michael Thomas, head of thoracic oncology at the Thoraxklinik - University of Heidelberg. Discover how targeted treatments and immuno-oncology are revolutionizing patient outcomes, with metastatic non-small cell lung cancer (mNSCLC) survival rates now exceeding 50% after 5 years in certain subgroups. Learn about extended genetic diagnostics techniques, including qPCR, digital PCR, Sanger Sequencing, and NGS, and their role in aligning with evolving targeted treatment options. Understand the impact of immune checkpoint inhibition (ICI) in mNSCLC patients with PD-L1 expression ≥ 50%, achieving a 30% 5-year survival probability. Examine the potential of perioperative ICI implementation in locoregional disease, including induction treatment strategies and the exploration of candidate biomarkers for patient stratification. Gain insights into how these parallel advancements in molecular diagnostics, targeted treatments, and ICI development are transforming the lung cancer treatment landscape.

The Evolving Landscape of Lung Cancer Treatment